NASDAQ:BTX - Brooklyn ImmunoTherapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$14.91
▼ -0.31 (-2.04%)
Get New Brooklyn ImmunoTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Brooklyn ImmunoTherapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.91.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in Brooklyn ImmunoTherapeutics. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2019HC WainwrightReiterated RatingBuyLow
i
Rating by J. Pantginis at HC Wainwright
2/7/2019Dawson JamesReiterated RatingBuyHigh
i
Rating by J. Kolbert at Dawson James
(Data available from 6/16/2016 forward)
Brooklyn ImmunoTherapeutics logo
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Read More

Today's Range

Now: $14.91
$14.26
$15.29

50 Day Range

MA: $0.96
$0.92
$0.99

52 Week Range

Now: $14.91
$0.66
$2.81

Volume

1,849,007 shs

Average Volume

6,876,669 shs

Market Capitalization

$636.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Brooklyn ImmunoTherapeutics?

The following equities research analysts have issued research reports on Brooklyn ImmunoTherapeutics in the last twelve months:
View the latest analyst ratings for BTX.

What is the current price target for Brooklyn ImmunoTherapeutics?

0 Wall Street analysts have set twelve-month price targets for Brooklyn ImmunoTherapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Brooklyn ImmunoTherapeutics in the next year.
View the latest price targets for BTX.

What is the current consensus analyst rating for Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BTX.

What other companies compete with Brooklyn ImmunoTherapeutics?

How do I contact Brooklyn ImmunoTherapeutics' investor relations team?

Brooklyn ImmunoTherapeutics' physical mailing address is 6965 El Camino Real SUITE 100, CARLSBAD CA, 92009. The company's listed phone number is 510-521-3390 and its investor relations email address is [email protected] The official website for Brooklyn ImmunoTherapeutics is www.biotimeinc.com.